These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38211468)

  • 1. HDAC-targeting epigenetic modulators for cancer immunotherapy.
    Cheng B; Pan W; Xiao Y; Ding Z; Zhou Y; Fei X; Liu J; Su Z; Peng X; Chen J
    Eur J Med Chem; 2024 Feb; 265():116129. PubMed ID: 38211468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy.
    Peng X; Pan W; Jiang F; Chen W; Qi Z; Peng W; Chen J
    Pharmacol Res; 2022 Dec; 186():106529. PubMed ID: 36328301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of class I HDAC modulators: Inhibitors and degraders.
    Huang Z; Zeng L; Cheng B; Li D
    Eur J Med Chem; 2024 Oct; 276():116696. PubMed ID: 39094429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator.
    Karati D; Mukherjee S; Roy S
    Med Oncol; 2024 Mar; 41(4):84. PubMed ID: 38438564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
    Smalley JP; Cowley SM; Hodgkinson JT
    Molecules; 2020 Sep; 25(19):. PubMed ID: 32987782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
    Park J; Thomas S; Munster PN
    Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual BET/HDAC inhibition to relieve neuropathic pain: Recent advances, perspectives, and future opportunities.
    Romanelli MN; Borgonetti V; Galeotti N
    Pharmacol Res; 2021 Nov; 173():105901. PubMed ID: 34547384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
    Peng X; Sun Z; Kuang P; Chen J
    Eur J Med Chem; 2020 Dec; 208():112831. PubMed ID: 32961382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
    Bai Y; Ahmad D; Wang T; Cui G; Li W
    Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment.
    Shirbhate E; Singh V; Jahoriya V; Mishra A; Veerasamy R; Tiwari AK; Rajak H
    Eur J Med Chem; 2024 Jan; 263():115938. PubMed ID: 37989059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
    Vaidya GN; Rana P; Venkatesh A; Chatterjee DR; Contractor D; Satpute DP; Nagpure M; Jain A; Kumar D
    Eur J Med Chem; 2021 Jan; 209():112844. PubMed ID: 33143937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC inhibitors and immunotherapy; a double edged sword?
    Kroesen M; Gielen P; Brok IC; Armandari I; Hoogerbrugge PM; Adema GJ
    Oncotarget; 2014 Aug; 5(16):6558-72. PubMed ID: 25115382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current trends in development of HDAC-based chemotherapeutics.
    Cheshmazar N; Hamzeh-Mivehroud M; Nozad Charoudeh H; Hemmati S; Melesina J; Dastmalchi S
    Life Sci; 2022 Nov; 308():120946. PubMed ID: 36096240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serendipitous discovery of Class I HDAC inhibitors from rational design of molecular glue degraders targeting HDAC.
    Chen D; Lin S; Zeng Z; An J; Yan W; Gu Z; Chen L; He B
    Eur J Med Chem; 2024 Jan; 263():115926. PubMed ID: 37995564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer.
    Hesham HM; Lasheen DS; Abouzid KAM
    Med Res Rev; 2018 Sep; 38(6):2058-2109. PubMed ID: 29733427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
    Chen J; Li Y; Zhang J; Zhang M; Wei A; Liu H; Xie Z; Ren W; Duan W; Zhang Z; Shen A; Hu Y
    Eur J Med Chem; 2021 Jan; 209():112868. PubMed ID: 33077265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer.
    Stazi G; Fioravanti R; Mai A; Mattevi A; Valente S
    Curr Opin Chem Biol; 2019 Jun; 50():89-100. PubMed ID: 30986654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibitors as epigenetic regulators for cancer immunotherapy.
    Conte M; De Palma R; Altucci L
    Int J Biochem Cell Biol; 2018 May; 98():65-74. PubMed ID: 29535070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.
    Grinshtein N; Rioseco CC; Marcellus R; Uehling D; Aman A; Lun X; Muto O; Podmore L; Lever J; Shen Y; Blough MD; Cairncross GJ; Robbins SM; Jones SJ; Marra MA; Al-Awar R; Senger DL; Kaplan DR
    Oncotarget; 2016 Sep; 7(37):59360-59376. PubMed ID: 27449082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present).
    Zhao C; Dong H; Xu Q; Zhang Y
    Expert Opin Ther Pat; 2020 Apr; 30(4):263-274. PubMed ID: 32008402
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.